


## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Single Technology Appraisal**

# Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430

## **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Amgen (inebilizumab)	All Wales Therapeutics and Toxicology     Centre
<ul> <li>Patient/carer groups</li> <li>Brain and Spine Foundation</li> <li>Brain Charity</li> <li>Carers UK</li> </ul>	<ul> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> </ul>
<ul> <li>Eyecare Trust</li> <li>Fight for Sight</li> <li>National Federation of the Blind of the UK</li> <li>Neurological Alliance</li> <li>Royal National Institute of Blind People</li> <li>SeeAbility</li> <li>Sense</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Thomas Pocklington Trust</li> </ul>	<ul> <li>Care Quality Commission</li> <li>Department of Health - Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Confederation</li> <li>NHS Wales Joint Commissioning Committee</li> <li>Scottish Medicines Consortium</li> <li>Welsh Government</li> </ul>
Transverse Myelitis Society	Relevant research groups
<ul> <li>Healthcare professional groups</li> <li>Association of British Neurologists</li> <li>Association of Optometrists</li> <li>British and Irish Orthoptic Society</li> <li>British Geriatrics Society</li> <li>British Neuropathological Society</li> <li>British Ophthalmic Anaesthesia Society</li> <li>College of Optometrists</li> <li>National Neurosciences Advisory Group</li> <li>Optical Confederation</li> <li>Primary Care and Community Neurology Society</li> <li>Royal College of General Practitioners</li> </ul>	<ul> <li>Brain Research UK</li> <li>Cochrane Eyes and Vision Group</li> <li>Eye Hope</li> <li>Genomics England</li> <li>Institute of Neurology</li> <li>Institute of Ophthalmology, University College London</li> <li>MRC Clinical Trials Unit</li> <li>National Eye Research Centre</li> <li>National Hospital for Neurology and Neurosurgery</li> <li>National Institute for Health Research</li> </ul>



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>Royal College of Nursing</li> <li>Royal College of Ophthalmologists</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>UK Clinical Pharmacy Association</li> </ul>	<ul> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>
Others  Department of Health and Social Care  NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).


### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These

Provisional stakeholder list for the evaluation of Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430

Issue date: November 2025





organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.